Patents are in place that prevent companies from making a generic Nesina (alogliptin) product at this time. However, after the first patent expires in March 2015, companies may be allowed to make generic versions. Although alogliptin is often referred to as the "generic name" for Nesina, it is simply the active ingredient and not a generic version of the drug.
Nesina® (alogliptin) is a prescription medication used in the treatment of type 2 diabetes. It belongs to a group of medicines known as dipeptidyl peptidase-4 inhibitors (more commonly called DPP-4 inhibitors or simply "gliptins").
Nesina is made by Takeda Pharmaceuticals America, Inc. It is currently protected from generic competition by patents that have not yet expired.
The first patent for Nesina currently expires in March 2015. The U.S. Food and Drug Administration lists several other patents for Nesina, many which expire earlier, but these patents are not specific to Nesina. March 2015 is the earliest predictable date that a generic version of this drug could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This includes such things as lawsuits or other patents for new Nesina uses. Once Nesina goes off-patent, there may be several companies that manufacture a generic Nesina drug.
No -- alogliptin is the active ingredient in Nesina, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer would make the product.